Skip to content

Medical emergency? What to do

Study challenges idea that schizophrenia is distinct in developing and developed regions

3-RXPublished March 15, 20073 min read

Key points

  • Research by the World Health Organization (WHO) has suggested that the course and symptomatic expression of schizophrenia is relatively more benign in developing societies.
  • The researchers point to the islands in Micronesia as an example of this variation.
  • The authors combined quantitative clinical diagnostic tools – of symptoms like poor impulse control and eye-tracking – with qualitative methods such as patient interviews.
  • Indeed, one of the few significant differences between the Palauan sample and the Western sample was the proportion of participants living at home.

Research by the World Health Organization (WHO) has suggested that the course and symptomatic expression of schizophrenia is relatively more benign in developing societies. However, a new study from Current Anthropology challenges this assumption, comparing biological and cultural indicators of schizophrenia in urban, Western societies with study data from the island of Palau, which has one of the highest rates of schizophrenia diagnosis in the world today.

“A 1% average worldwide population prevalence of schizophrenia is routinely interpreted in the medical literature as implying a uniform distribution,” write Roger J. Sullivan (California State University, Sacramento), John S. Allen (University of Southern California), and Karen L. Nero (University of Canterbury, New Zealand). “In this sense, the 1% figure is a myth that conceals considerable variability in actual prevalence between settings.”

The researchers point to the islands in Micronesia as an example of this variation. Prevalence of schizophrenia ranges from a low of 0.4% in the Marshall Islands to 1.7% in the western Republic of Palau – a more than fourfold difference. The expression of schizophrenia in Palau and greater Micronesia is also extraordinarily gendered, with rates of affliction approximately two times higher among males than among females.

“Recognizing this high variability in prevalence between populations is important,” write the researchers, “. . . Genetic perspectives tend to emphasize uniformity in prevalence and symptomatic expression while contextual sociocultural perspectives tend to emphasize variability.”

The authors combined quantitative clinical diagnostic tools – of symptoms like poor impulse control and eye-tracking – with qualitative methods such as patient interviews. Compared to a sample of New Yorkers and other similar studies in New Zealand and Scotland, their findings challenge the idea put forth by the WHO and other research that schizophrenia in developing regions is distinct from and more benign than schizophrenia in developed regions. The researchers also dispute the common assumption that schizophrenia in developing nations is a consequence of development.

“These analyses have identified unique aspects of the expression of schizophrenia in Palau, but more striking to us are the similarities that emerge when comparing the Palauan data with research findings in [Western] settings,” the authors write.

Indeed, one of the few significant differences between the Palauan sample and the Western sample was the proportion of participants living at home. (Eighty-seven percent of the Palauan participants lived at home.) Notably, “extensive kin-based levels of support” have been cited by the WHO to explain the supposedly more benign expression of schizophrenia in developing regions.

###

University of Chicago Press Journals

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.